Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
Eligibility
Participation Requirements
Sex: All
View:
• Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Locations
Other Locations
China
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING
Beijing
Contact Information
Primary
Zhijie Wang, MD
jie_969@163.com
+86 13466323860
Time Frame
Start Date: 2026-02-28
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 109
Treatments
Extension Cohort
Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Related Therapeutic Areas
Sponsors
Leads: Cancer Institute and Hospital, Chinese Academy of Medical Sciences